首页> Journal for immunotherapy of cancer> First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors.

First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors.

导出 LinkOut

翻译打印收藏纠错

第一作者： Martin,Wermke

第一单位： Department of Medicine I, University Hospital Carl Gustav Carus, Dresden, Germany Martin.Wermke@uniklinikum-dresden.de.;National Center for Tumor Diseases, Dresden, Germany.

作者： Martin,Wermke ^[1] ; Tobias A W,Holderried ^[2] ; Jason John,Luke ^[3] ; Van K,Morris ^[4] ; Winfried H,Alsdorf ^[5] ; Katrin,Wetzko ^[6] ; Borje S,Andersson ^[7] ; Ignacio I,Wistuba ^[8] ; Edwin R,Parra ^[8] ; Mohammad B,Hossain ^[9] ; Sandra,Grund-Gröschke ^[10] ; Katrin,Aslan ^[10] ; Arun,Satelli ^[9] ; Anantha,Marisetty ^[9] ; Swapna,Satam ^[10] ; Mamta,Kalra ^[9] ; Jens,Hukelmann ^[10] ; M Alper,Kursunel ^[10] ; Karine,Pozo ^[9] ; Andreas,Acs ^[10] ; Linus,Backert ^[10] ; Melissa,Baumeister ^[10] ; Sebastian,Bunk ^[10] ; Claudia,Wagner ^[10] ; Oliver,Schoor ^[10] ; Ali S,Mohamed ^[9] ; Andrea,Mayer-Mokler ^[10] ; Norbert,Hilf ^[10] ; Delfi,Krishna ^[9] ; Steffen,Walter ^[9] ; Apostolia M,Tsimberidou ^[11] ; Cedrik M,Britten ^[10]

作者单位： Department of Medicine I, University Hospital Carl Gustav Carus, Dresden, Germany Martin.Wermke@uniklinikum-dresden.de.;National Center for Tumor Diseases, Dresden, Germany. ^[1] Department of Hematology, Oncology, Immunooncology, Stem Cell Transplantation, and Rheumatology, University Hospital Bonn, Bonn, Germany. ^[2] Cancer Immunotherapeutics Center, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA. ^[3] Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center Division of Cancer Medicine, Houston, Texas, USA. ^[4] Department of Oncology, Hematology, and Bone Marrow Transplantation with Section Pneumology, University Hospital Hamburg-Eppendorf, Hamburg, Germany. ^[5] Department of Medicine I, University Hospital Carl Gustav Carus, Dresden, Germany. ^[6] The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. ^[7] Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. ^[8] Immatics US, Inc, Houston, Texas, USA. ^[9] Immatics Biotechnologies GmbH, Tuebingen, Germany. ^[10] Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, Texas, USA. ^[11]

关键词 Adoptive cell therapy - ACT Solid tumor T cell Receptor - TCR

医学主题词人类(Humans);女(雌)性(Female);男(雄)性(Male);抗原, 肿瘤(Antigens, Neoplasm);中年人(Middle Aged);老年人(Aged);肿瘤(Neoplasms);成年人(Adult);免疫疗法, 过继(Immunotherapy, Adoptive);受体, 抗原, T细胞(Receptors, Antigen, T-Cell);肿瘤蛋白质类(Neoplasm Proteins)

DOI 10.1136/jitc-2023-008668

PMID 39038917

发布时间 2025-08-27

基金项目

P30 CA016672/CA/NCI NIH HHS/United States UM1 TR004906/TR/NCATS NIH HHS/United States

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Journal for immunotherapy of cancer

2024年12卷7期

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览0

Journal for immunotherapy of cancer

2024年12卷7期

检索历史清除

First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors.

Journal for immunotherapy of cancer

相似文献

同项目论文

Journal for immunotherapy of cancer

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors.

Journal for immunotherapy of cancer

相似文献

同项目论文

Journal for immunotherapy of cancer

相关期刊

检索历史清除